Strategies and challenges for the next generation of therapeutic antibodies
Strategies and challenges for the next generation of therapeutic antibodies
复制标题
DOI：
10.1038/nri2747
复制
发表时间：
2010-05-01
影响因子：
100.3
通讯作者：
Corvaia, Nathalie
中科院分区：
文献类型：
--
作者：
Beck, Alain;Wurch, Thierry;Corvaia, Nathalie
抗体和相关产品是增长最快的一类治疗剂。通过分析过去10年中基于IgG的生物制剂的监管批准，我们可以深入了解制药公司迄今为止将创新药物推向市场的成功策略。在未来十年中，将不得不面临许多挑战，以将更有效和负担得起的基于抗体的药物推向临床。在这里，我们讨论的策略，以选择最好的治疗抗原的目标，优化IgG抗体的结构和设计相关的或新的结构与其他功能。
Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.